Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Resources

The latest in from biologics discovery and development through to production and supply chain management.

Top R&D Stories of 2023

Through captivating articles, insight pieces, and spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year.
Read Now
Peptides

The Future of Peptide Chemistry and Sustainability

The peptide market is continually developing, but how are manufacturers responding to its new requirements and altering the landscape of peptide manufacturing?
Read More
Bispecifics

Regeneron’s New Bispecific: A Toxic Success?

Regeneron announced that their bispecific odronextamab had the highest recorded complete response rate for follicular lymphoma, but the therapeutic antibody’s safety profile has thrown up several concerns.
Read More
Vaccines

Dual-Action Malaria Vaccine Takes the Punch out of the Parasite

A new vaccine duo developed by scientists at George Washington University stops malaria infection and transmission, the double attack needed to eradicate the disease.
Read More
Vaccines

Nexelis’s Collaborative Development for Optimal Clinical Assay

November’s webinar, Adaptive Laboratory Environment: Collaboration Across our Development Teams Produces Optimal Clinical Assay, discusses Nexelis’s process in recombinant protein production, optimisation, and characterisation.
Read More
Vaccines

Overcoming Vaccine Manufacturing Challenges

Experts from King’s College London, Janssen, and Merck Sharp & Dohme congregate to talk the future of optimised vaccine manufacturing.
Read More
Vaccines

Vaccines After COVID: How the Pandemic Has Changed the Vaccination Market

During the pandemic, a layperson couldn't avoid learning about vaccinations. But as the world returns to “normal”, how does this new-found focus on vaccines manifest for regulators, producers, prescribers, and the public? 
Read More
Vaccines

Vaccines Europe: Presentations You Won’t Want to Miss

Find out about some of Oxford Global’s most highly anticipated presentations happening at our upcoming Vaccines Congress.
Read More
Proteins & Antibodies

Roche Fail to Follow in Eisai’s Footsteps: Alzheimer’s Drug Flunks Phase III Trials

Roche revealed that they will stop all Alzheimer’s trials after anti-amyloid beta antibody gantenerumab fails Phase III trials.
Read More
Proteins & Antibodies

Heart-to-Heart or Head-to-Head: Amgen Heart Drug to Challenge Novartis

New data released from Amgen’s phase II study of olpasiran suggests that the drug could fill a niche in the cardiovascular market.
Read More
Vaccines

Universal Vaccines & Vaccine Therapeutics

Mark Doherty, Senior Medical Manager at GSK, leads a Discussion Group on leveraging the mechanisms of action in therapeutic vaccine development.
Read More
Proteins & Antibodies

AbbVie Ditch Phase II Autoimmune Drug

AbbVie announced that they are dropping the ROR? inverse agonist, marking the end of their collaboration with Inventiva
Read More
Bispecifics

Exploring & Developing Various Biotherapeutic Modalities

Galahad Deperalta, Senior Scientist and Innovation Group Leader at Genentech, leads a Discussion Group on the next generation of biotherapeutic development.
Read More

Subscribe to Our Newsletter

Sign up for our monthly newsletter to
keep up with all things biologics